bluuebunny/crossref_metadata_2025 huggingface dataset:
Temozolomide Combined with Radiotherapy in the Treatment of Recurrent Cranial Meningioma Previously Treated with Multiple Surgical Resections and Two Sessions of Radiosurgery: A Case Report and Literature Review
Authors: Scorsetti Marta , Alongi Filippo , Clerici Elena , Navarria Pierina , Simonelli Matteo , Rognone Elisa , Santoro Armando
Published: February 2018

Meningioma is a common primary brain tumor in adults. The treatment approach depends on its grade, size and symptoms. The case reported here was a repeatedly recurring transitional meningioma, previously treated with several surgical procedures and two sessions of cranial radiosurgery. At the time of last relapse, temozolomide was administered alone and combined with external beam radiation therapy. At the last follow-up after 38 months, the disease was stable. In conclusion, in this case of plurirecurrent meningioma, treatment with temozolomide alone and in combination with radiotherapy was feasible and associated with limited morbidity, providing clinical benefit and long local disease control. We discuss the case comparing our approach with other experiences reported in the literature.
Clinical Evaluation of the Accuracy of an Invasive Frame Designed for Stereotactic Intracranial Radiosurgery Treatment with Helical Tomotherapy
Authors: Zeverino Michele , Barra Salvina , Taccini Gianni
Published: February 2018

Aims and background

The study focused on the evaluation of the accuracy of intracranial stereotactic radiosurgery treatments delivered with helical tomotherapy by means of the InterFix™ Radiosurgery kit.

Methods and study design

Twenty-two patients received stereotactic radiosurgery treatments with single fraction dose ranging from 13 to 20 Gy depending on diagnosis. Megavoltage computed tomography scans performed prior the treatments were analyzed in order to determine the position accuracy. For 8 selected cases, they were also performed at the end of the treatment to evaluate the intra-fraction motion.

Results

Mean setup errors and standard deviations were −1.6 ± 2.2 mm, −0.2 ± 1.2 mm, 0.4 ± 1.3 mm, 0.2 ± 0.5° for the lateral (IEC-x), longitudinal (IEC-y), vertical (IEC-z) directions and rotational variation (roll), respectively. Setup error was found to be greater than 3 mm-PTV expansion in 36% of the cases. Mean intra-fraction motion was 0.5 ± 0.7 mm, −0.3 ± 0.4 mm, 0.1 ± 0.5 mm and 0.1 ± 0.2° for the IEC-x, IEC-y, IEC-z and roll, respectively.

Conclusions

Observed intra-fraction movements of less than 1 mm suggested the use of the tested fixation device for stereotactic radiosurgery treatment on helical tomotherapy providing that the image-guidance procedure is always performed prior to treatment.
A Unique Case of Blastoid Variant of Mantle Cell Lymphoma with an Aberrant CD5-/CD10+/Bcl-6+/CD56+ Immunophenotype: A Case Report
Authors: Park Sanghui , Ko Young Hyeh
Published: February 2018

The neural adhesion molecule CD56 is normally expressed on natural killer cells and subsets of T cells and is commonly found in hematolymphoid neoplasms. Expression of CD56 is very rare in B-cell lymphoma and most reported CD56-positive cases were diffuse large B-cell lymphomas. Cases of CD56-positive mantle cell lymphoma (MCL) have not previously been described in the literature. We present a case of CD56-positive MCL. To the best of our knowledge, this is the first case report of MCL expressing CD56.
Transanal Tube NO COIL® after Rectal Cancer Proctectomy. The “G. Paolo II” Cancer Centre Experience
Authors: Montemurro Severino , De Luca Raffaele , Caliandro Cosimo , Ruggieri Eustachio , Rucci Antonello , Sciscio Vito , Ranaldo Nunzio , Federici Antonio
Published: February 2018

Aims and background

Covering stoma is the main method used to protect low-lying anastomosis after cancer proctectomy. Intraluminal rectal pressure could be a potential risk factor for anastomotic leakage. We present our personal experience with an alternative and original device, the transanal tube NO COIL®, evaluating its feasibility and safety based on a preliminary manometric study.

Methods

From May 1998 to March 1999, an experimental manometric study on 35 subjects was performed to assess the pathophysiological basis of intraluminal rectal pressure with or without the transanal tube. Subsequently, from April 1999 to December 2009, 184 patients (107 males, 77 females, average age 68.2 ± 10 years) with primary adenocarcinoma of the rectum (≤12 cm from anal verge) were selected. Eighty-two underwent total proctectomy and 102 subtotal proctectomy. No stoma were fashioned. At the end of the operation, the silicone transanal tube NO COIL®, 60–80 mm long, 2 mm thick with a calibre of up to 2 cm, was applied and secured to the perineal skin by two stitches, then removed on the seventhpostoperative day if no signs of leakage occurred.

Results

The intraluminal rectal pressure with transanal tube was strongly reduced from 13.8 + 8.5 mmHg to 4.8 + 3.7 mmHg (P <0.01). Nine patients (4.8%) developed an anastomotic leakage, 2 males and 7 females. In 10 patients, the transanal tube NO COIL® did not remain in situ for the planned seven days, and 18 patients suffered from ulcers in the perianal skin. Leakage subsided with conservative treatment in 4 patients, whereas 5 patients required loop colostomy. The stoma rate was 2.7%. No leakage-related deaths occurred, and overall mortality was 1.3%.

Conclusions

The transanal tube NO COIL® does not abolish the risk of anastomotic leakage but could be an alternative option to covering stoma after cancer proctectomy in selected patients. In our experience, this simple and cheap device could reduce the rate of stoma without leakage-related mortality. Further studies within a randomized controlled trial are required to better define our results.
Expression and Mutation Analyses of Fas, FLIP and Bcl-2 in Granulosa Cell Tumor of Ovary
Authors: Yoo Nam Jin , Kim Min Sung , Lee Sug Hyung
Published: February 2018

Aims and background

Mounting evidence indicates that evasion of apoptosis contributes to tumor pathogenesis. Although both Fas and Bcl-2 are crucial in apoptosis of normal ovarian cells, their roles in ovarian tumors, especially stromal tumors, are largely unknown. The aim of this study was to explore mutation of the Fas gene and expression of the apoptosis-related proteins Fas, FLICE-like inhibitory protein (FLIP) and Bcl-2 in granulosa cell tumor (GCT) of the ovary.

Methods

We analyzed the expression of Fas, FLIP and Bcl-2 in 20 GCT tissues by immunohistochemistry. We also analyzed somatic mutations of the Fas gene in the same GCT tissues by polymerase chain reaction and single-strand conformation polymorphism assay.

Results

Expression of Fas was evident in 12 GCTs (60%), but the remaining 8 GCTs showed no or markedly decreased Fas immunostaining. Expression of FLIP was identified in 30% of the GCT samples and expression of Bcl-2 in 75%. All GCTs with positive Fas expression (n = 12) showed either FLIP or Bcl-2 expression. The GCTs were found to carry no somatic Fas mutations.

Conclusions

Our data show that alterations of the apoptosis-related proteins Fas, FLIP and Bcl-2 are common in GCT, and suggest that expression of FLIP and Bcl-2 and loss of Fas expression might play role in the pathogenesis of GCT, possibly by inhibiting apoptosis.
Synchronous Presentation of Hepatoid Alpha-Fetoprotein-Producing Lung Cancer and Colorectal Adenocarcinoma
Authors: Valentino Francesco , Torchio Martina , Morbini Patrizia , Danova Marco
Published: February 2018

We describe the synchronous presentation of hepatoid adenocarcinoma of the lung and colorectal adenocarcinoma in a patient with elevated alpha-fetoprotein (AFP) serum levels. Our patient was treated after surgery with a conventional chemotherapy regimen including bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, which was demonstrated to improve the clinical results in the treatment of colorectal and lung cancer compared with chemotherapy alone, and is today approved both for colon and lung cancer.

Besides the unconventional association of the two cancer types in our patient and the unsatisfactory clinical benefit obtained with the medical treatment administered, we report on the significance of AFP serum levels as a tumor marker in this peculiar situation. In our patient these levels, monitored from the first clinical symptoms through the last chemotherapy course, did not show any correlation with the response to treatment or with the patient's overall outcome. In particular, the serum marker remained essentially unchanged after the surgical removal of the lung mass and the subsequent chemotherapy.
Osteosarcoma of the Pelvis: A Monoinstitutional Experience in Patients Younger than 41 Years
Authors: Ferrari Stefano , Palmerini Emanuela , Fabbri Nicola , Staals Eric , Ferrari Cristina , Alberghini Marco , Picci Piero
Published: February 2018

Aims and background

Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30–40 years.

Methods

Data on patients <41 years of age with high-grade pelvic osteosarcoma were prospectively collected. Patients received two chemotherapy protocols consisting of methotrexate, cisplatin, doxorubicin (MAP) and standard-dose or high-dose ifosfamide.

Results

Forty patients between 11 and 36 years were included. The most frequent histological subtype was osteoblastic followed by chondroblastic (37.5%). Complete surgical remission was achieved in 65% of patients. Eighteen patients had MAP/standard-dose ifosfamide, 22 MAP/high-dose ifosfamide. Primary chemotherapy was given to 25 patients and 6 (24%) of them had a good histological response. Median follow-up was 32 months (range, 4–134). Five-year overall survival was 27.5%: 33% in localized and 0 in metastatic patients (P = 0.02); 45% in patients with complete surgical remission and 0 for patients without complete surgical remission (P = 0.001). Local recurrence rate was 46%. In patients with complete surgical remission, 5-year overall survival was 32% with MAP/standard-dose ifosfamide and 59% with MAP/high-dose ifosfamide regimen (P = 0.3).

Conclusions

Local control is the major issue in the treatment of pelvic osteosarcoma. Poor pathological response and high incidence of chondroblastic variant indicate different characteristics between pelvic and extremity osteosarcoma. Chemotherapy with MAP and high-dose ifosfamide might be beneficial in patients with pelvic osteosarcoma and warrants further investigation.
Survival in Patients with Newly Diagnosed Conventional Glioblastoma: A Modified Prognostic Score Based on a Single-Institution Series
Authors: Bertolini Federica , Zunarelli Elena , Baraldi Caterina , Valentini Antonella , Del Giovane Cinzia , Depenni Roberta , Falasca Angelo , Giacobazzi Patrizia , Malagoli Marcella , Meletti Stefano , Fontana Annalisa , Conte PierFranco
Published: February 2018

Aims and background

Recursive partioning analysis (RPA) is commonly used to define the stratification of patients with glioblastoma. Epigenetic silencing of the O6-methylguanine methyltransferase (MGMT) gene by promoter methylation plays an important role in regulating MGMT expression in gliomas and this is an established independent prognostic factor. We tested a prognostic scoring system including all clinical variables used by RPA classification (age, ECOG performance status and type of surgery) and MGMT gene promoter methylation status.

Methods

Seventy-eight consecutive patients with newly diagnosed, histopathologically confirmed conventional glioblastoma were included. Information about MGMT promoter methylation status was available for all of them. Based on the patients' age (<50 vs ≥50 years), ECOG performance status (0 vs ≥1), type of surgery (gross tumor resection versus partial resection/biopsy) and MGMT promoter methylation status (methylated versus unmethylated), three classes of risk were generated where the prognostic score was defined assigning 1 point to every favorable parameter (Class I: ≥3; Class II: 2; Class III: 0–1). All classes were correlated with overall survival.

Results

The median survival times were 32.4, 8.6 and 8.8 months for Class I, II and III, respectively, corresponding to 2-year survival rates of 69%, 13.5% and <1%. The same analysis was performed on 54 patients treated with postoperative concomitant chemoradiotherapy. The median survival times were 32.5, 13.4 and 8.9 months for Class I, II and III, respectively, corresponding to 2-year survival rates of 68.6%, 26.9% and <1%. In both groups of 78 and 54 patients the differences in survival between Class I and III were statistically significant (P <0.0001).

Conclusions

The proposed prognostic scoring system including clinical variables and MGMT promoter methylation status proved valuable in patients with primary conventional glioblastoma, especially those treated with postoperative chemoradiotherapy.
Irinotecan during pregnancy in metastatic colon cancer
Authors: Cirillo Massimo , Musola Mariella , Cassandrini Paola Agnese , Lunardi Gianluigi , Venturini Marco
Published: February 2018

Background

Colon cancer during pregnancy is a relatively rare occurrence. To date there has been sparse clinical evidence about the safety of chemotherapy in this setting because the available data derive only from single-institution case reports.

Methods

Irinotecan and fluorouracil, as part of the FOLFIRI regimen, were administered to a 33-year-old pregnant woman at an estimated gestational age of 23+ weeks. She had been diagnosed with adenocarcinoma of the transverse colon with liver and lymph node metastases.

Results

Chemotherapy was administered from the 23+th to the 28+th week of gestational age. Chemotherapy was stopped because of disease progression. At 30 weeks' gestational age, the patient underwent an emergency cesarean section and colon resection. She gave birth to a healthy male infant with no particular problems in neurological, respiratory, cardiovascular, digestive and nutritional function. At follow-up, the 13-month-old child had achieved all appropriate growth and developmental milestones.

Conclusions

Our report demonstrates the safety of exposure to FOLFIRI for both mother and fetus. The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy.
Primary Cardiac Myxofibrosarcoma: A Case Report and Review of the Literature
Authors: Wang Ji-Gang , Li Yu-Jun , Liu Hui , Zhao Peng
Published: February 2018

Aims and background

Primary myxofibrosarcoma of the heart is a rare malignancy. To the best of our knowledge, no more than 17 cases have been reported since 1963.

Methods and study design

We report the case of a 42-year-old man who presented with dyspnea and palpitation of one month's duration. Echocardiography and enhanced computed tomography revealed a large tumor in the left atrium.

Results

The patient underwent palliative excision of the tumor and histopathological analysis revealed it to be a low-grade myxofibrosarcoma. The patient developed a bone metastasis two years later and is still alive 26 months after the cardiac surgery.

Conclusions

Primary cardiac myxofibrosarcoma involves predominantly the left atrium and the most common symptom induced by the tumor is dyspnea. Disease outcome is often disappointing despite aggressive postoperative radiotherapy and chemotherapy.
Abdominal Cocoon: A Potential Pitfall in Patients with Ovarian Carcinoma
Authors: Isacson Rut , Segal Amiel , Alberton Joseph , Reinus Constantin , Schwarz Alon , Grenader Tal
Published: February 2018

Background

Abdominal cocoon, or sclerosing encapsulating peritonitis, is a rare condition characterized by partial or total encasement of small bowel and mesentery by a thick fibrocollagenous sack that looks like a cocoon. Within the sack, bowel loops are drawn together causing intestinal obstruction.

Case presentation

We report on a 57-year-old female patient who developed a very unusual complication of ovarian cancer: abdominal cocoon formation.

Conclusions

This report highlights the need for a timely diagnosis of sclerosing encapsulating peritonitis in cancer patients.
Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back
Authors: Yilmaz Yusuf , Colak Yasar , Kurt Ramazan , Senates Ebubekir , Eren Fatih
Published: February 2018

Aims and background

Nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are two major causes of liver disease worldwide. Epidemiological and clinical data have clearly demonstrated that NAFLD and its associated metabolic abnormalities are a risk factor for HCC. Traditionally, the mechanisms whereby NAFLD acts as a risk for HCC are believed to include replicative senescence of steatotic hepatocytes and compensatory hyperplasia of progenitor cells as a reaction to chronic hepatic injury. Recent years have witnessed significant advances in our understanding of the mechanisms underlying the link between NAFLD and HCC.

Methods

In the present review, we provide an update on the pathophysiological pathways linking NAFLD and its associated metabolic derangements to malignant hepatic transformation, with a special focus on insulin resistance, adipokines, inflammation, and angiogenesis. We will also discuss the potential therapeutic implications that such molecular links carry.

Results

Although treating NAFLD could reduce the risk of malignant hepatic transformation, no long-term studies focusing on this issue have been conducted thus far. Insulin resistance, inflammation as well as derangements in adipokines and angiogenic factors associated with NAFLD are closely intertwined with the risk of developing HCC.

Conclusions

Traditional therapeutic approaches in NAFLD including metformin and statins may theoretically reduce the risk of HCC by acting on common pathophysiological pathways shared by NAFLD and HCC.
Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM)
Authors:   behalf of the AIOM Working Group “Interaction with Regional Sections” (2009–2011), Gori Stefania , Di Maio Massimo , Pinto Carmine , Alabiso Oscar , Baldini Editta , Barbato Enrico , Beretta Giordano Domenico , Bravi Stefano , Caffo Orazio , Canobbio Luciano , Carrozza Francesco , Cinieri Saverio , Cruciani Giorgio , Dinota Angelo , Gebbia Vittorio , Giustini Lucio , Graiff Claudio , Molino Annamaria , Muggiano Antonio , Pandoli Giuliano , Puglisi Fabio , Tagliaferri Pierosandro , Tomao Silverio , Lunardi Gianluigi , Venturini Marco
Published: February 2018

Aims and background

In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices.

Methods and study design

A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures.

Results

Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17%) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The medical oncologist played a major role in the communication with patients (73% alone and a further 24% in cooperation with other professional figures) and was the point of reference in the event of side effects in 97% of cases. In most cases, the reimbursement of drug costs was separated (“File F” procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access.

Conclusions

Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.
Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey
Authors:   on behalf of AIOM Lombardia, Cortinovis Diego , Beretta Giordano , Piazza Elena , Luchena Giovanna , Aglione Stefania , Bertolini Alessandro , Buzzoni Roberto , Cabiddu Mary , Carnaghi Carlo , Danova Marco , Farina Gabriella , Ferrari Vittorio , Frascaroli Mara , Reni Michele , Tansini Giuseppe
Published: February 2018

Aims and background

Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior.

Methods

To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members.

Results

From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases.

Conclusions

Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.
125I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience
Authors: Guarneri Alessia , Botticella Angela , Filippi Andrea Riccardo , Munoz Fernando , Beltramo Giancarlo , Casetta Giovanni , Giglioli Francesca Romana , Tizzani Alessandro , Ragona Riccardo , Ricardi Umberto
Published: February 2018

Aims and background

To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125I permanent brachytherapy at the University of Turin.

Methods and study design

A retrospective analysis was carried out on 167 consecutive patients with early stage prostate adenocarcinoma who underwent 125I brachytherapy between January 2003 and December 2010. A minimum follow-up of ≥12 months was mandatory for inclusion. Biochemical disease-free survival (defined on the basis of the ASTRO definition and the ASTRO-Phoenix definition) was chosen as the primary end point. Secondary end points were gastrointestinal and genitourinary toxicity (acute and late, defined according to the RTOG scale).

Results

With a median follow-up of 42 months (range, 13.5–90.7), biochemical disease-free survival at 3 and 5 years was respectively 91.1% and 85.7%, according to the ASTRO definition and 94.5% and 85.1% according to ASTRO-Phoenix definition (for statistical purposes, only the ASTRO definition was used). Hormone treatment and nadir PSA (cutoff of 0.35 ng/ml) were the only factors affecting biochemical disease-free survival both on univariate ( P = 0.02 and P = 0.001, respectively) and multivariate analysis (HR 0.024; P = 0.021 and HR 21.6; P = 0.006, respectively). Only 3.6% of patients experienced ≥grade 3 acute urinary toxicity and 5% ≥grade 3 late urinary toxicity. Prior transurethral prostate resection was the only independent predictor of grade 3 late urinary toxicity on multivariate analysis (HR 0.13; P = 0.009).

Conclusions

This mono-institutional series confirmed that brachytherapy is an effective and safe treatment modality for localized prostate cancer, with acceptable short- and long-term morbidity rates.
Clinical Significance of CD44 Variants Expression in Colorectal Cancer
Authors: Li Xiao-Dong , Ji Mei , Wu Jun , Jiang Jing-Ting , Wu Chang-Ping
Published: February 2018

Aims and background

We designed the present study to observe CD44s and CD44v6 expressions in colorectal cancer and evaluate their clinical value.

Methods

CD44s and CD44v6 expression in colorectal cancer tissues were examined by an immunohistochemical test. Survival analysis was performed with the Kaplan-Meier method, and the differences between the CD44-positive and -negative groups were evaluated with the logrank test.

Results

The positive rates of CD44s and CD44v6 were 66.7% and 63.2%, respectively. There were significant associations between CD44s positive expression and Dukes’ stage or tumor differentiation. There were significant associations between CD44v6 positive expression and tumor differentiation, Dukes’ stage and lymph node metastasis. There was a significant difference in the 5-year survival rates between CD44v6-positive and CD44v6-negative groups (52.78% and 80.95%, respectively), but not between CD44s-positive and CD44s-negative groups (55.26% and 78.95%, respectively). Multivariate analysis indicated that CD44v6 positive expression predicts a poor prognosis.

Conclusions

CD44s and CD44v6 play important roles in the infiltration and metastasis of colorectal cancer. CD44v6 positive expression can be a predictor for a poor prognosis.
Leptomeningeal Metastasis from Prostate Cancer
Authors: Cante Domenico , Franco Pierfrancesco , Sciacero Piera , Girelli Giuseppe , Borca Valeria Casanova , Pasquino Massimo , Migliaccio Fernanda , Tofani Santi , Grassi Lucia , Marra Annamaria , Ozzello Franca , La Porta Maria Rosa , Ricardi Umberto
Published: February 2018

Aims and background

Metastatic prostate carcinoma commonly involves bones and extrapelvic lymph nodes, with occasional visceral deposits. Central nervous system involvement is unusual and particularly the occurrence of leptomeningeal metastasis (LM) is extremely rare, with few cases described in the medical literature. The clinical presentation is characterized by multifocal neurological deficit and the prognosis is generally dismal, with survival ranging between 3 and 6 months. We report on a patient affected by LM due to prostate cancer who was treated with a combined-modality approach consisting of sequential chemotherapy and radiotherapy.

Methods

A 70-year-old man was referred to our group for cognitive mental disorder, left-sided frontal headache and nausea; the patient had a previous history of metastatic prostate cancer. LM was diagnosed neuroradiologically with brain MRI and evidence of a detectable level of PSA in the cerebrospinal fluid. He was treated with docetaxel and prednisone for 3 cycles followed by external beam radiotherapy (EBRT) to the whole brain to a total dose of 30 Gy in 10 fractions with a simultaneous integrated boost to the macroscopic disease (total dose of 35 Gy in 10 fractions). No acute toxicity was observed.

Results

A substantial clinical response was obtained after EBRT with neurological improvement and radiologically stable disease at post-treatment imaging until 10 weeks after radiation. The patient died of sudden general condition deterioration 3 months after EBRT.

Conclusion

Since LM derived from prostate cancer is likely to become a more common clinical event, such patients would need to be included in clinical trials evaluating new therapeutic approaches, considering that the current treatment strategies have been shown to be rather ineffective.
Primitive Neuroectodermal Tumor (PNET) as Somatic-Type Malignancy Arising from an Extragonadal Germ-Cell Tumor: Clinical, Pathological and Molecular Features of a Case
Authors: Garg Amit , Nahal Ayoub , Turcotte Robert , Tabah Roger , Alcindor Thierry
Published: February 2018

We report a rare case of a 34-year-old man with a right axillary mass. Ten years previously, he had been diagnosed with a right scapular nonseminomatous germ-cell tumor consisting of teratoma, completely resected without any further treatment. Presently he was found to have a metastatic malignant small round cell tumor consistent with a secondary somatic malignancy arising in the background of nonseminomatous germ-cell tumor, teratoma, yolk sac tumor, and primitive neuroectodermal tumor with distinct chromosome 22 translocation. Although the patient initially responded well to chemotherapy with etoposide, cisplatin, ifosfamide and mesna, he relapsed shortly after.
One-Day DCF Regimen in Patients with Metastatic Gastric Cancer
Authors: Dirican Ahmet , Kucukzeybek Yuksel , Tarhan Mustafa Oktay , Somali Isil , Erten Cigdem , Demir Lutfiye , Can Alper , Bayoglu Ibrahim Vedat , Akyol Murat , Ekinci Nese , Medeni Murat , Koyuncu Betul , Alacacioglu Ahmet
Published: February 2018

Background

Cytotoxic chemotherapy is the basic treatment for metastatic gastric cancer. The “docetaxel, cisplatin, 5-day infusion of 5-FU (DCF5)” regimen is regarded as an effective therapy. However, the poor toxicity profile of this regimen and administration by 5-day infusion are major drawbacks of this method.

Methods

Patients with measurable metastatic gastric carcinoma, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, normal hematological and renal function, adequate hepatic function, and not pretreated for advanced disease with chemotherapy, received docetaxel on day 1, cisplatin on day 1, and 5-FU peripheral IV on day 1 (DCF1) every 3 weeks. The patients undergoing the DCF1 regimen could not receive the infusion regimen. This was a retrospective study about the use of DCF in 1 day in not previously treated metastatic gastric cancer.

Results

In total, 95 patients were treated with a median of 5 cycles per patient. Those not previously treated for advanced disease received docetaxel 75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1, and 5-FU peripheral IV 750 mg/m2/day on day 1, plus filgrastim or lenograstim between days 3 and 7. Grade ≥3 toxicities were neutropenia (12%), anemia (11%), thrombocytopenia (3%), fatigue (18%), mucositis (10%), diarrhea (3%), nausea/vomiting (6%), neurological (3%), and palmar-plantar (2%). Two nonfatal febrile neutropenia episodes were recorded. There were no treatment-related deaths. In all patients with measurable disease, we observed an overall response rate of 46% (40 partial responses, 4 complete responses). Thirty-one patients (33%) had stable disease. The median overall survival was 9.0 months (95% CI 7.34–10.6).

Conclusions

Use of the DCF1 regimen in metastatic gastric cancer is feasible, with comparable activity to previous results achieved with epirubicin-based chemotherapy and infusion DCF in terms of overall survival. However, randomized and prospective studies need to be carried out with this regimen.
Total Mesorectal Excision for Rectal Cancer: Laparoscopic versus Open Approach
Authors: Ying Xiaojiang , Li Zhenjun , Shen Yi , Ye Pingjiang , Pan Weihuo , Chen Hongliang , Zhang Lihua
Published: February 2018

Aims and background

To evaluate the oncologic safety of laparoscopic total mesorectal excision for rectal cancer.

Methods and study design

Patients who underwent laparoscopic (n = 256) or open (n = 173) total mesorectal excision for rectal cancer between June 2005 and June 2011 were included. Long-term survival operative data and postoperative recovery were retrospectively reviewed from a prospectively collected database.

Results

No significant difference was found between the two groups in terms of age, sex, tumor stage and preoperative comorbidities. Twelve patients were converted to open procedures. Differences were found in blood loss (55 ± 14.1 vs 152 ± 29.2 ml P <0.05), infection of incision (3.1% vs 12.7%, P <0.05) and postoperative stay (8.1 ± 3.0 vs 12.4 ± 6.3 days, P <0.05). Both groups were comparable regarding lymph node clearance specimen length and distal margin. There was no significant difference in overall survival between the two groups by the life-table method. However, operative time in the laparoscopic group was longer than in the open group (168 ± 27.6 vs 141 ± 21.9 min, P <0.05).

Conclusions

Laparoscopic total mesorectal excision for rectal cancer offers oncologic results similar to those obtained with the open procedure with a favorable short-term outcome. Continued use of the procedure in these patients is supported.
Antitumor Effect of Japanese Apricot Extract (MK615) on Human Cancer Cells in Vitro and in Vivo through a Reactive Oxygen Species-Dependent Mechanism
Authors: Hattori Miho , Kawakami Koshi , Akimoto Miho , Takenaga Keizo , Suzumiya Junji , Honma Yoshio
Published: February 2018

Aims and background

MK615 is produced from Japanese apricot and contains several cyclic triterpenes, such as oleanolic and ursolic acids. MK615 was shown to strongly suppress cutaneous in-transit metastasis in a patient with malignant melanoma. The present investigation was undertaken to clarify the antitumor effects of MK615 in vitro and in vivo.

Methods

Several human cancer cell lines were exposed to MK615 for 7 days to examine its antiproliferative effects. The effect of MK615 on in vivo growth of human pancreatic cancer MIAPaCa-2 cells was also examined.

Results

MK615 inhibited the growth of several human cancer cell lines in a concentration-dependent way. Pancreatic cancer MIAPaCa-2 cells were highly sensitive to the growth-inhibiting effects of MK615. Treatment with MK615 preferentially induced cell death in human cancer cells while sparing normal cells such as human umbilical vein endothelial cells (HUVEC) and mouse bone marrow cells. When MIAPaCa-2 cells were incubated with MK615 in the presence of antioxidant, growth-inhibition was significantly reduced, and MK615 induced the accumulation of reactive oxygen species in cancer cells but not in HUVEC. MK615, in both the presence and absence of gemcitabine, significantly inhibited the growth of human pancreatic cancer cells as xenografts without apparent adverse effects.

Conclusions

MK615, a supplement produced from Japanese apricot, may have therapeutic value in treating human cancers through a reactive oxygen species-dependent mechanism.
Pretreatment CA 15-3 Levels do not Predict Disease-Free Survival in Patients with Advanced Epithelial Ovarian Cancer
Authors: Gemer Ofer , Oustinov Natalia , Gdalevich Michael , Dubnik Serge , Levy Roni , Yachnin Adela , Lavie Ofer , Baruch Noa Ben , Arie Alon Ben
Published: February 2018

Aims

To evaluate the role of pretreatment CA 15-3 levels as a predictor of disease-free survival in patients with advanced epithelial ovarian cancer.

Methods

A cohort of 65 patients with FIGO stage III or IV epithelial ovarian cancer was evaluated. Patients were treated either with primary cytoreductive surgery followed by adjuvant platinum-based chemotherapy or with neoadjuvant chemotherapy with interval debulking surgery. All patients had pretreatment CA 15-3 and CA 125 tumor marker determinations. The patients were divided into a group with elevated CA 15–3 and a group with normal levels. The two groups were compared with regard to clinical and survival measures.

Results

The patients' median age was 65 years (range, 37–90); 34 (52%) were at stage III and 31 (48%) at stage IV. CA 15–3 was elevated (>30 units/mL) in 44 (68%) patients, with a median level of 39 units (range, 4-2282). CA 125 was elevated (>35 units/mL) in 61 (94%) patients, with a median level of 947 units (range, 4-30,642). CA 125 and CA 15-3 levels were not correlated (r = 0.015, P = 0.332). The median follow-up was 22 months (range, 3–120 months). Fifty-three (81%) patients had disease recurrence and 43 (66%) died. Survival analysis showed that patients with elevated and normal CA 15-3 levels had similar recurrence-free survival ( P = 0.78) and overall survival ( P = 0.55).

Conclusions

Although elevated in the majority of patients with advanced epithelial ovarian cancer, CA 15-3 levels are not predictive of survival.
Transsternal Surgical Biopsy of a Mediastinal Mass under Local Anesthesia
Authors: Bedini Amedeo Vittorio , Libretti Lidia , Pirondini Emanuele
Published: February 2018

We describe a minimally invasive transsternal surgical approach to obtain biopsies from retrosternal masses under local anesthesia. This original procedure was carried out in a patient with superior vena cava syndrome because she was unfit to undergo a CT-guided biopsy and at high risk for narcosis. In patients with such features this procedure could be preferable to conventional techniques. The transsternal approach is reliable, produces minimal trauma and no risk of pleural or vessel injury, and is very fast.
Uncommon Synchronous Association between Ovarian Carcinoma and Gastrointestinal Stromal Tumor: A Case Study and Literature Review
Authors: Favero Giovanni , Pfiffer Tatiana , Riedlinger Wolfram FJ , Chiantera Vito , Schneider Achim
Published: February 2018

Background

The association of gastrointestinal stromal tumors (GIST) and other cancers is well known, but its synchronous occurrence with gynecological malignancies is very uncommon. Usually, the diagnosis is accidentally established. We describe a patient with GIST and concurrent ovarian cancer and discuss the clinical implications of this finding.

Case report

A 64-year-old woman with a prior diagnosis of ovarian cancer developed a second recurrence after having undergone two operations and adjuvant chemotherapy. While tumor debulking was performed, a small, nonsuspicious lesion was removed from the greater curvature of the stomach. Histology revealed a GIST.

Conclusion

The association of GIST and ovarian cancer is a rarity and its synchronicity may alter the oncological prognosis and therapy of the patient.
Estimates of cancer burden in Lazio
Authors: Rashid Ivan , Pannozzo Fabio , Rossi Silvia , Foschi Roberto
Published: February 2018

Aims and background

Since 1983 a population-based cancer registry has been operating in Lazio which provides incidence and survival data and covers the entire Latina province, amounting to 10% of the regional population. The aim of this paper is to provide estimates of the incidence, mortality and prevalence for seven major cancers in the Lazio region for the period 1970—2015.

Methods

The estimates were obtained by applying the MIAMOD method, a statistical back-calculation approach to derive incidence and prevalence figures starting from mortality and relative survival data. Survival was modeled on the basis of published data from the Italian cancer registries.

Results

In 2012 the most frequent cancer sites were breast, colon-rectum and prostate with 5,529, 5,315 and 4,759 new diagnosed cases, respectively. The cancers with increasing incidence trends were breast cancer, lung cancer and skin melanoma in women, and prostate cancer, colorectal cancer and melanoma in men. The incidence rates of uterine cervix and stomach cancer decreased. The male lung cancer rates increased, reaching a peak in the late 1980s, and then decreased. Prevalence increased for all the considered cancers except cervix cancer. In 2012 breast, colorectal and prostate cancer had the highest prevalence, with 68,239, 36,617 and 33,934 prevalent cases, respectively. In the final period of the study the mortality declined for all cancers except female lung cancer. In 2012, the highest mortality rates were estimated for lung cancer in both men and women, with 89 and 40 deaths per 100,000, respectively.

Conclusion

These estimates give a useful description of the present and future cancer patterns in the Lazio region. Incidence, mortality and prevalence projections provide new information for health resource planning. Furthermore, they point to the need to reinforce the organized screening programs, especially for breast and colorectal cancer.
Estimates of cancer burden in Campania
Authors: Fusco Mario , De Angelis Roberta , Senatore Gennaro , Zigon Giulia , Rossi Silvia
Published: February 2018

Aims and background

In Campania two cancer registries have been operating since 1996, covering part of the province of Naples and the province of Salerno, and amounting to 29% of the regional population. The aim of this paper is to provide estimates of the incidence, mortality and prevalence of seven major cancers for the entire Campania region.

Methods

The estimates were obtained by applying the MIAMOD method, a statistical back-calculation approach to derive incidence and prevalence figures starting from mortality and relative survival data. Survival was modeled on the basis of published data from the Italian cancer registries.

Results

In 2012 the most frequent cancers were colorectal, breast and lung cancer with 3,969, 3,675 and 3,629 new diagnosed cases, respectively. The cancers with increasing incidence trends were breast cancer, lung cancer and skin melanoma in women, and colorectal cancer and skin melanoma in men. By contrast, the incidence rates of uterine cervix cancer and stomach cancer were decreasing. In men the lung and prostate cancer incidence rates increased, reaching a peak in different periods, and then decreased and stabilized, respectively. Prevalence was increasing for all considered cancers with the exception of cervical cancer. The highest values in 2012 were estimated for breast and colorectal cancer (34,000 and 22,000 prevalent cases, respectively). In the final period under study there was a decline in mortality for all cancers except female lung cancer. The highest crude mortality rates in 2012 were estimated for lung cancer in men and breast cancer in women: 80 and 31 per 100,000, respectively.

Conclusion

This paper provides a description of the burden of the major cancers in Campania until 2015. The estimates highlight the need to reinforce organized screening, especially for breast and colorectal cancer, and to support evidence-based prevention campaigns against female smoking. All these aspects require continuous and updated monitoring of the main epidemiological indicators in the Campania population.
Estimates of cancer burden in Basilicata and Calabria
Authors: Galasso Rocco , Capocaccia Riccardo , Del Riccio Luciana , Viviano Lorena , Matera Rosa , Rossi Silvia
Published: February 2018

Aims and background

Basilicata and Calabria are two neighboring, low income regions of southern peninsular Italy with an overall population of about 2.5 million in 2010. Cancer registration has covered the entire Basilicata population since 2005 and the province of Catanzaro (18.3% of the Calabria population) since 2003. This paper will provide estimates and projections for the period 1970—2015 of the basic epidemiological indicators — incidence, prevalence and mortality — in the Basilicata and Calabria regions for the major cancers (lung, colon and rectum, stomach, skin melanoma, breast, cervix and prostate).

Methods

The indicators were estimated by applying the MIAMOD statistical back-calculation method to the 1970—2002 official mortality data, and to the 1985—2002 relative survival data collected by population-based registries of the southern regions of Italy.

Results

The incidence rates were estimated to be still rising for breast, prostate and colorectal cancer, and for skin melanoma in men. By contrast, they were estimated to be declining for cervix and stomach cancer. The incidence increased, reaching a peak, and subsequently decreased for lung cancer in men and for skin melanoma in women. The age-standardized mortality rates were estimated to decrease for all considered cancers except prostate cancer in men and lung cancer in women, which presented quite stable mortality rates from the mid 2000s onwards. Except for cervix cancer, prevalence was increasing for all considered cancers, particularly those of the breast and prostate.

Conclusion

These data support the need for health policies focused on primary and secondary prevention, which is the main way to reduce the overall impact of cancer and to preserve health care resources, as well as on actions aimed at ensuring equal access to cancer care and at transferring innovation into clinical practice.
Estimates of cancer burden in Sicily
Authors: Tumino Rosario , Capocaccia Riccardo , Traina Adele , Madeddu Anselmo , Contrino Maria Lia , Zigon Giulia
Published: February 2018

Aims and background

Estimates are complementary epidemiological measures which allow to present data on cancer burden, especially in geographical areas where measurements of cancer occurrence are not supported by exhaustive statistics on incidence, mortality and survival. The aim of this paper is to provide cancer incidence, mortality and prevalence estimates and projections for the major cancers in the period 1970—2015 for the entire region of Sicily.

Methods

The estimates were computed by applying the MIAMOD method, a statistical back-calculation approach to derive incidence and prevalence figures starting from mortality and relative survival data. Published data from the Italian cancer registries were modeled in order to estimate the regional cancer survival.

Results

In 2012 the most common cancers were breast cancer in women, colorectal cancer in both sexes, and prostate cancer in men, with about 4,000, 3,500 and 3,000 estimated new cases, respectively. The highest crude mortality rates were estimated for lung cancer in men (63.6 per 100,000) and breast cancer in women (30.8 per 100,000) and the lowest for skin melanoma (both sexes) and cancer of the cervix uteri. For colorectal, lung and stomach cancer and skin melanoma, all the indicators were higher in men than women. The prevalence figures in women were more than 9 times the incidence figures for breast cancer and more than 10 times the incidence figures for skin melanoma. The prevalence was twice the incidence for lung cancer in both sexes. The prevalence increased for all the considered cancers except cervical cancer.

Conclusion

According to our analyses in Sicily we expect about 14,000 new diagnoses and 5,500 deaths for the major cancer types in a year, while about 92,000 persons with a diagnosis of the considered cancers were alive in 2012. We expect an increase in cancer survival and contemporary aging of the population: both expectations will inflate the cancer prevalence, causing more demand for oncology facilities.